These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15782758)

  • 1. [Latanoprost topical ophthalmic combinations].
    Călugăru M; Călugăru D
    Oftalmologia; 2004; 48(4):18-28. PubMed ID: 15782758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
    Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
    Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
    Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brimonidine and latanoprost as adjunctive therapy.
    Camras CB
    Ophthalmology; 2004 Feb; 111(2):410-1. PubMed ID: 15019405
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of latanoprost, brimonidine and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension.
    Orzalesi N; Rossetti I; Bottoli A; Invernizzi T; Fumagalli E; Fogagnolo P
    Acta Ophthalmol Scand Suppl; 2002; 236():55. PubMed ID: 12390144
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
    Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JN
    Eye (Lond); 2004 Oct; 18(10):990-5. PubMed ID: 15037890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%.
    Alward WL
    Am J Ophthalmol; 2001 Sep; 132(3):449-51. PubMed ID: 11554384
    [No Abstract]   [Full Text] [Related]  

  • 8. Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%.
    Eisenberg DL
    Am J Ophthalmol; 2001 Sep; 132(3):448-9. PubMed ID: 11554383
    [No Abstract]   [Full Text] [Related]  

  • 9. Substituting latanoprost (Xalatan) for isopropyl unoprostone (Rescula) in monotherapy and combination therapy.
    Tsukamoto H; Yokoyama T; Okada K; Okada M; Mochizuki H; Mishima HK
    Acta Ophthalmol Scand; 2000 Oct; 78(5):604-5. PubMed ID: 11037926
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP; Söderström M; Rouland JF; Malecaze F
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
    Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents.
    Hoyng PF; Rulo A; Greve E; Watson P; Alm A
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S93-8. PubMed ID: 9154283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brimonidine and latanoprost as adjunctive therapy.
    Camras CB
    Ophthalmology; 2003 Jan; 110(1):6-8; author reply 8-9. PubMed ID: 12511334
    [No Abstract]   [Full Text] [Related]  

  • 18. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
    Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
    Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Br J Ophthalmol; 2010 Jan; 94(1):80-4. PubMed ID: 19692375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
    Bucci MG
    J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.